Tissue factor pathway inhibitor-2 was repressed by CpG hypermethylation through inhibition of KLF6 binding in highly invasive breast cancer cells
2007

How DNA Methylation Affects TFPI-2 in Breast Cancer

publication Evidence: moderate

Author Information

Author(s): Guo Hongshen, Lin Yifeng, Zhang Hongwei, Liu Juan, Zhang Nong, Li Yiming, Kong Desheng, Tang Qiqun, Ma Duan

Primary Institution: Fudan University

Hypothesis

Both genetic variations and DNA hypermethylation might contribute to the down regulation of TFPI-2 during the progression of breast cancer.

Conclusion

The down regulation of TFPI-2 in highly metastatic breast cancer is due to abnormal hypermethylation in the CpG dinucleotides of the KLF-6 binding site.

Supporting Evidence

  • TFPI-2 was not detected in the highly invasive breast cancer cell line MDA-MB-435.
  • Hypermethylation of the TFPI-2 promoter was observed in MDA-MB-435 cells.
  • KLF6 binding to the TFPI-2 promoter was diminished due to CpG methylation.

Takeaway

In some breast cancer cells, a gene that helps control tumor growth is turned off because of changes in its DNA. This happens when certain parts of the DNA get covered up, preventing important helpers from doing their job.

Methodology

The study involved analyzing the expression of TFPI-2 in breast cancer cell lines, examining genetic variations in the promoter region, and assessing the effects of DNA methylation on KLF6 binding.

Limitations

The study primarily focused on specific breast cancer cell lines and may not represent all breast cancer types.

Statistical Information

P-Value

0.342

Statistical Significance

p<0.05

Digital Object Identifier (DOI)

10.1186/1471-2199-8-110

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication